Terms: = Endocrine gland cancer AND TOP2A, TOP2, TP2A AND Diagnosis
11 results:
1. Identification of key genes and pathways in adrenocortical carcinoma: evidence from bioinformatic analysis.
Yin M; Wang Y; Ren X; Han M; Li S; Liang R; Wang G; Gang X
Front Endocrinol (Lausanne); 2023; 14():1250033. PubMed ID: 38053725
[TBL] [Abstract] [Full Text] [Related]
2. RHPN1‑AS1 promotes ovarian carcinogenesis by sponging miR‑6884‑5p thus releasing top2a mRNA.
Cui S; Li F
Oncol Rep; 2021 Oct; 46(4):. PubMed ID: 34414458
[TBL] [Abstract] [Full Text] [Related]
3. Identification of hub genes and pathways in adrenocortical carcinoma by integrated bioinformatic analysis.
Guo J; Gu Y; Ma X; Zhang L; Li H; Yan Z; Han Y; Xie L; Guo X
J Cell Mol Med; 2020 Apr; 24(8):4428-4438. PubMed ID: 32147961
[TBL] [Abstract] [Full Text] [Related]
4. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract] [Full Text] [Related]
5. Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis.
Shen J; Yu S; Sun X; Yin M; Fei J; Zhou J
J Ovarian Res; 2019 Nov; 12(1):110. PubMed ID: 31729978
[TBL] [Abstract] [Full Text] [Related]
6. Identification of potential core genes and miRNAs in testicular seminoma via bioinformatics analysis.
Wang K; Chen Y; Zhao Z; Feng M; Zhang S
Mol Med Rep; 2019 Nov; 20(5):4013-4022. PubMed ID: 31545448
[TBL] [Abstract] [Full Text] [Related]
7. The growth inhibitory effect of gambogic acid on pancreatic cancer cells.
Youns M; ElKhoely A; Kamel R
Naunyn Schmiedebergs Arch Pharmacol; 2018 May; 391(5):551-560. PubMed ID: 29546614
[TBL] [Abstract] [Full Text] [Related]
8. Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer.
Bai Y; Li LD; Li J; Lu X
J Ovarian Res; 2016 Jun; 9(1):35. PubMed ID: 27315793
[TBL] [Abstract] [Full Text] [Related]
9. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.
Sherman-Baust CA; Kuhn E; Valle BL; Shih IeM; Kurman RJ; Wang TL; Amano T; Ko MS; Miyoshi I; Araki Y; Lehrmann E; Zhang Y; Becker KG; Morin PJ
J Pathol; 2014 Jul; 233(3):228-37. PubMed ID: 24652535
[TBL] [Abstract] [Full Text] [Related]
10. Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas.
Zajchowski DA; Karlan BY; Shawver LK
Mol Cancer Ther; 2012 Feb; 11(2):492-502. PubMed ID: 22203729
[TBL] [Abstract] [Full Text] [Related]
11. A molecular expression signature distinguishing follicular lesions in thyroid carcinoma using preamplification RT-PCR in archival samples.
Denning KM; Smyth PC; Cahill SF; Finn SP; Conlon E; Li J; Flavin RJ; Aherne ST; Guenther SM; Ferlinz A; O'Leary JJ; Sheils OM
Mod Pathol; 2007 Oct; 20(10):1095-102. PubMed ID: 17660800
[TBL] [Abstract] [Full Text] [Related]
